Clinical Report: FDA Approves Dual-Energy Catheter Ablation Platform
Overview
The FDA has approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, enabling electrophysiologists to utilize both pulsed field and radiofrequency energy through a single catheter.
Background
The approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform represents a significant advancement in catheter ablation technology, which is crucial for treating arrhythmias. The ability to deliver both pulsed field and radiofrequency energy allows for tailored approaches based on individual patient anatomy and procedural complexity.
Data Highlights
No numerical data available in the source material.
Key Findings
- The platform integrates pulsed field and radiofrequency energy delivery into a single catheter.
- It is compatible with the CARTO ecosystem, enhancing mapping and imaging capabilities.
- More than one million patients have been treated with the THERMOCOOL SMARTTOUCH SF catheter platform in the US.
- The first US procedures using the platform are expected to begin in summer 2023.
- Electrophysiologists can choose the energy type based on the needs of each procedure.
Clinical Implications
The Dual Energy THERMOCOOL SMARTTOUCH SF Platform allows electrophysiologists to choose the energy type based on the needs of each procedure.
Conclusion
The FDA's approval of this dual-energy platform marks a development in catheter ablation technology.
Related Resources & Content
- Johnson & Johnson, FDA, 2026 -- Approval of Dual Energy THERMOCOOL SMARTTOUCH SF System
- UCI Health, Advances in catheter ablation, 2023 -- Pioneering new techniques
- Clinical Research in Cardiology, Comparative Outcomes at 12 Months, 2024 -- Novel Radiofrequency Balloon and Cryoballoon Technologies
- Clinical Research in Cardiology, Insights Gained from Catheter Ablation, 2021 -- Ventricular Arrhythmias in Patients with LVADs
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation, PMC -- Clinical Practice Guidelines
- Clinical Research in Cardiology — Clinical Outcomes in Patients Exhibiting Dual Conduction Pathways in the Atrioventricular Node: Findings from a Multicenter Observational Study
- Premarket Approval (PMA)
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - PMC
- https://academic.oup.com/europace/article/27/8/euaf179/8234088
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
